Loading
A private hospital in Abu Dhabi whose cancer institute gives chemotherapy, radiotherapy and, since 2026, radiopharmaceutical treatment for some cancers that have spread. It is a site for international breast and lung cancer trials.
In its UICC directory entry (updated May 2026) Burjeel Medical City describes diagnosis, staging and treatment of solid tumours and blood cancers, a weekly multidisciplinary meeting with radiology, pathology, radiation and PET services, neoadjuvant, adjuvant and palliative chemotherapy, a tumour registry that reports to the Department of Health, and free screening and awareness days. IAEA DIRAC, read on 11 November 2026 with the entry updated in 2025, lists the Burjeel Cancer Institute with two linear accelerators and a CT scanner. In October 2026 the Abu Dhabi Media Office reported that the institute had introduced therapeutic radiopharmaceuticals, delivered in Burjeel Medical City's nuclear medicine department, for patients with tumours that express the target receptors. ClinicalTrials.gov lists it as a site of the heredERA trial of giredestrant in HER2-positive breast cancer (NCT05296798) and of the trial of sacituzumab tirumotecan with pembrolizumab in squamous lung cancer (NCT06422143).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/